SCHEMBL5481486

SCHEMBL5481486

COC(=O)c1ccoc1CSc1nc2cc(C)c(C)cc2[nH]1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.53
HTT P42858 2/20 0.53
GAA P10253 2/20 0.53
TSHR P16473 1/20 0.53
RAB9A P51151 5/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
NPC1 O15118 2/20 0.52
GFER P55789 1/20 0.49
MAPT P10636 3/20 0.47
ALDH1A1 P00352 2/20 0.46
PRMT5 O14744 7/20 0.45
WDR77 Q9BQA1 6/20 0.45
RECQL P46063 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
HRH4 Q9H3N8 1/20 0.43
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5478987 0.85 RAB9A (0.64) LMNAHTTGAATSHRRAB9A
SCHEMBL5485409 0.81 RAB9A (0.56) LMNAHTTGAATSHRRAB9A
SCHEMBL5489719 0.74 MAPT (0.48) LMNAHTTGAATSHRRAB9A
SCHEMBL3378206 0.72 CYP2C9 (0.50) LMNAHTTGAATSHRRAB9A
SCHEMBL10333608 0.70 HSD17B10 (0.46) LMNAHTTGAATSHRRAB9A
SCHEMBL5479006 0.69 RAB9A (0.52) LMNAHTTGAATSHRRAB9A
SCHEMBL5472719 0.69 PRMT5 (0.54) LMNAHTTGAATSHRRAB9A
SCHEMBL15693657 0.69 CYP2E1 (0.71) LMNARAB9ASMN1; SMN2NPC1MEN1
SCHEMBL7822536 0.69 PRKAG1 (0.69) LMNATSHRRAB9ASMN1; SMN2NPC1
SCHEMBL5475794 0.68 SMN1; SMN2 (0.56) LMNAHTTGAATSHRRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275995-A1 Thiobenzimidazole derivatives TEIJIN PHARMA LIMITED 2007-11-29 US disclosed
US-7268145-B2 Thiobenzimidazole derivatives TEIJIN PHARMA LIMITED (JP) 2007-09-11 US disclosed
US-20060040976-A1 Thiobenzimidazole derivatives TEIJIN LIMITED 2006-02-23 US disclosed
US-20050267148-A1 Benzimidazole derivative TEIJIN LIMITED 2005-12-01 US disclosed
EP-1097926-A1 THIOBENZIMIDAZOLE DERIVATIVES TEIJIN LIMITED (JP) 2001-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275995-A1 Thiobenzimidazole derivatives CMA1, SERPINB1, TMPRSS15 LMNA 4278/4885HTT 2600/4885GAA 94/4885
US-20060040976-A1 Thiobenzimidazole derivatives CMA1, SERPINB1, TMPRSS15 LMNA 4278/4885HTT 2600/4885GAA 94/4885
US-20050267148-A1 Benzimidazole derivative CMA1, SERPINB1, TPSAB1 LMNA 3900/4885HTT 3473/4885GAA 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.